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1. Introduction
Until recently, medical care in sub-Saharan Africa (SSA) has ad-
dressed the immediate demands of Human Immunodeﬁciency Virus
(HIV), Tuberculosis, Malaria and Maternal–Child Health. Though these
challenges remain, the region has had a degree of success in these ef-
forts, and suﬃcient urbanization and economic development that an
epidemiologic transformation, in which people live long enough to
develop cancer and other non-communicable diseases, is well underway
in SSA (Binagwaho, 2012).
The care of patients with cancer is one of the great challenges and
achievements of modern society. It requires speciﬁc, coordinated mul-
tidisciplinary care from highly trained specialists, extensive infra-
structure and a detailed and nuanced understanding of both the in-
dividual patient and the population at hand. In high-income countries
(HICs), the care of patients with cancer is costly and highly resource
intense, and often based on a speciﬁc molecular or genetic defect.
The treatment of cancer in the resource-limited context of SSA,
therefore, presents a tremendous challenge. A simple transposition of
protocols and technologies from HICs would be impractical and in-
humane; resources would rapidly be depleted and many patients would
remain without care. Other models have been developed that better
match their setting, and this is as it should be. The challenges of
biology, resources and human capacity found in SSA are such that ef-
fective solutions should be and, in fact, can only be developed in SSA.
For this reason it is imperative that multifaceted research be developed
in step with clinical cancer care in SSA (Varmus & Trimble, 2011). Here
we review some of those challenges and opportunities.
The reader should note that the region of SSA is a huge and vastly
diverse one, containing multiple sub-regions, 47 countries and ap-
proximately one billion people. To discuss cancer care and research in
SSA is to broadly generalize as much as it might be to discuss cancer
care in other WHO designated regions. Despite this signiﬁcant
limitation, however, we believe that some common challenges exist
across the region, and that by exploring them we may be ready to more
eﬀectively address them.
2. What is the burden of women's cancers in SSA?
Cervical and breast cancers are consistently the two most common
cancers in women across SSA (Wabinga et al., 2014; Mpunga et al.,
2014; Ferlay et al., 2015). The incidence and mortality of cervical
cancer are both far higher in SSA than is seen in more developed re-
gions, while breast cancer has been observed to present in more ad-
vanced stage and to carry a far higher case fatality rate than that seen in
other regions. The mortality from cervical cancer in Eastern and
Southern Africa for example is 18 times higher than that seen in Wes-
tern Asia and Western Europe. Similarly, though the rate of breast
cancer is lower in SSA than in more developed regions, the mortality is
still high: in Western Asia the age adjusted breast cancer mortality is 6
per 100,000 women, while in Western Africa it is 20 per 100, 000.
Though ovarian and endometrial cancers seem to be less common in
LMICs than in more developed countries, these diseases are regularly
encountered and create considerable burdens and challenges for pa-
tients and practitioners (del Carmen et al., 2015).
3. What is the capacity for care of patients with cancer in SSA?
Farmer has observed that eﬀective health care delivery requires
space, staﬀ, stuﬀ and systems (Stulac et al., 2015). To this one might
add a ﬁfth ‘s’: $ (or funding). The delivery of cancer care in SSA is
challenged by shortages of physical infrastructure, human resources,
equipment, validated standard operating procedures, and funding.
Though most nations in SSA have pledged to commit 10% of their
budgets to healthcare, current budget allocations are generally sig-
niﬁcantly lower (Morhason-Bello et al., 2013), and ministers of health
http://dx.doi.org/10.1016/j.gore.2017.06.002
Received 28 February 2017; Received in revised form 26 May 2017; Accepted 2 June 2017
⁎ Corresponding author at: Division of Gynecologic Oncology, The Massachusetts General Hospital, Boston, MA, United States.
E-mail address: trandall@mgh.harvard.edu (T.C. Randall).
Gynecologic Oncology Reports 21 (2017) 109–113
Available online 24 June 2017
2352-5789/ © 2017 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/BY-NC-ND/4.0/).
MARK
must manage these limited funds to address a broad range of diseases.
The WHO has documented the severe shortages of nurses and physi-
cians across SSA, and the ﬁndings are concerning (Organization WH,
2016). Kinfu and colleagues evaluated the number of physicians in 12
SSA countries and compared the number being trained to two estimates
of attrition (Yohannes Kinfu et al., 2009). They found that these
countries on average had 0.09 physicians per 1000 population, com-
pared to the U.S. which has over 26 times as many physicians at 2.4 per
1000 population. The number of nurses and midwives in SSA is 0.55 per
1000 population, compared to 9.8 in the U.S. Of more concern is the
fact that most countries studied had an inﬂow of doctors and nurses
that was either at or actually below estimated outﬂow of health per-
sonnel from the workforce. Figs. 1 and 2 show pictographically that the
rates of cervical cancer mortality in SSA are among the highest in the
world, while the supply of physicians is among the world's lowest.
These levels are far below recommendations, let alone the numbers
found in HICs. Holmer and colleagues recently evaluated the global
distribution of surgical specialists and found that LMICs, with 48% of
the world's global population, have only 20% of the world's surgical
specialists. This includes 19% of the world's surgeons, 15% of the an-
esthesiologists and 29% of the world's obstetricians (Hampus
Holmeremail et al., 2015). Disparities also exist within LMICs, with SSA
having some of the lowest densities of specialists seen. In Uganda, for
example, there are 0.6 surgeons and 0.3 obstetricians per 100,000
people, while in Nicaragua these numbers 8.7 and 4.5 and in the U.S.
they are 36.1 and 12.6. Medical staﬀ in SSA is therefore both over-
burdened clinically and less available for specialty training.
Freestanding cancer centers are uncommon in SSA and therefore
often face an overwhelming volume of patients. Stefan reviewed the
published literature and the internet and found only 102 cancer pro-
grams across Africa, despite an expected annual cancer related mor-
tality of nearly 600,000 in the region (Stefan, 2015). Outside of these
facilities, practitioners must balance the demands of more acute patient
needs against the ongoing needs of cancer patients. For example, gen-
eral surgeons may commonly be forced to delay a woman's mastectomy
to attend to another patient with an appendiceal abscess, while women
needing a radical hysterectomy for cervical cancer may be delayed due
to obstetric or gynecological emergencies. There are shortages of che-
motherapy, operating theaters and surgical equipment. Perhaps the
starkest example of equipment shortage in SSA in radiotherapy: while
the International Atomic Energy Commission recommends a radio-
therapy facility for every 250,000 to 500,000 people, in Africa there are
140 facilities for a population of over 1.2 billion. Zubizaretta and col-
leagues estimate that 407 facilities, running 12 h a day, would be
needed to meet the current needs for radiotherapy in Africa
(Zubizarreta & Lievens, 2016). In North America, by contrast, there are
2787 radiotherapy facilities while only 1200 would be needed to meet
current demand. Abdel-Wahab surveyed radiotherapy needs in Africa
and noted that out of 52 countries assessed, 23 had teletherapy and
only 20 had brachytherapy (Abdel-Wahab et al., 2013). Thus, few
people in Africa have access to standard radiotherapy for diseases such
as cervical cancer that require treatment with both teletherapy and
brachytherapy.
This deﬁcit of equipment and facilities further compounds the
challenge of building human capacity; there are many specialized
personnel, such as radiation physicists, radiotherapy technicians, and
pharmacy staﬀ qualiﬁed to work with chemotherapy, who have no
training opportunities or job prospects in such a setting. The initiation
Fig. 1. Pictograph of deaths from cervical cancer mapped
as land area of aﬀected countries. Low- and middle-income
countries are disproportionately aﬀected.
Fig. 2. Pictograph of physicians working depicted as land
area of the respective nations. Sub-Saharan Africa, with the
highest rates of cervical cancer deaths in the world, has the
fewest physicians.
Both images reproduced from Worldmapper.org with per-
mission.
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and scale up of programs therefore requires a carefully coordinated
development of physical resources, human resources and eﬀective
medical systems, such as record keeping and standard operating pro-
cedures for speciﬁc services.
4. Why must research be an integral component of capacity
building in SSA?
We believe that research can and must be developed in step with
clinical cancer care in Africa for several reasons. First, the biology of
common cancers may arguably be signiﬁcantly diﬀerent in SSA. Due to
both geography and levels of human development, people may more
commonly have signiﬁcant co-infections, such as parasitic infections,
that might aﬀect their clinical course. Second, what we know from
clinical experience and from clinical trials is based on very speciﬁc and
rariﬁed care delivery models in high-income settings; it is important to
study how diﬀerences in delivery models and settings alter the eﬀec-
tiveness of therapy. Third, while models of care delivery in HICs has
largely developed as a sort of ‘natural experiment’ over time, studies are
needed of implementation, quality improvement, patient experience
and other areas, to accelerate the development of optimal care given
speciﬁc settings and resources.
5. Cancer research in SSA
The African Organization for Research and Training in Cancer
(AORTIC) has performed an inventory of cancer research and clinical
care centers in Africa (Gueye et al., 2012). We recommend that in-
vestigators exploring possible projects in SSA search the AORTIC
handbook for ongoing projects and existing investigators with whom
they might collaborate. A signiﬁcant challenge to both research and
clinical care in SSA is the ‘silo’ eﬀect, in which multiple parties both
from within and outside SSA have parallel, non-coordinated and po-
tentially competing eﬀorts. To address this the U.S. National Cancer
Institute and the non-proﬁt ‘Global Oncology!’ collaborated to create
the Global Cancer Project Map (GCPM): http://globalonc.org/Projects/
global-cancer-project-map/ The GCPM includes data gathered by the
African Organization for Research and Training in Cancer (see below).
We encourage investigators to enter their work on the GCPM and to
utilize this resource in their searches for collaborators and to determine
what work is ongoing before initiating an isolated project.
Cancer research in SSA faces the same challenges as clinical care.
Investigators are largely left to look to HICs for funding. Most oncology
specialists face greater patient demands than are seen in HICs, leaving
limited time for research. For the most part, investigators must work
with lesser facilities, in terms of physical space, administrative support
such institutional review boards, and equipment when compared to
their HIC counterparts, with whom they are competing for funding.
6. Partnerships can strengthen research and clinical capacity
Many cancer centers and universities in SSA have been able to more
eﬀectively develop programs and obtain funding through leveraging
the expertise of partners at HIC universities. These partnerships have
often developed utilizing infrastructure built from funding and colla-
borations to combat HIV in SSA.
The Uganda Cancer Institute and the Fred Hutchinson Cancer
Institute of the University of Washington developed a highly productive
collaboration (Coghill et al., 2013). They have developed a clinical
oncology fellowship. The fellows are trained predominantly in Uganda
but travel to the Fred Hutchinson Center for additional training in
clinical oncology and research methods. Utilizing this collaboration, the
Uganda Cancer Institute has fully trained eight Ugandan clinical on-
cologists, as well as providing oncology education to over 200 Ugandan
scientists and 50 Ugandan physicians. Through this collaboration, key
ﬁndings in infection-related malignancy as well as the clinical
manifestations of malignancy in this environment have been published
(UCI/Hutchinson Center Cancer Alliance, n.d.).
A similar collaboration developed at the Academic Model of
Providing Access to Healthcare (AMPATH), at Moi University in
Eldoret, Kenya. This program is of particular interest to gynecologic
cancer specialists. Here, the Obstetrics and Gynecology faculty worked
with the University of Toronto's Gynecologic Oncology faculty to de-
velop a gynecologic oncology fellowship on site. Similar to the clinical
oncology program at UCI, the gynecologic oncology fellows were
trained by their senior faculty at Moi and by regular visits from the
University of Toronto faculty to teach in the clinic, on the wards and in
the operating theater. When the outside faculty were not on site, they
continued to give lectures, hold tumor boards and review the patients
on service on a daily to weekly basis (Elit et al., 2010).
The International Gynecologic Cancer Society (IGCS) currently has
an initiative to support such partnership-based gynecologic oncology
fellowships (Chuang et al., 2016). The IGCS has worked with colla-
borators to create a modiﬁable curriculum, suggesting areas of study
and the roles of the partners, faculty and trainees. The goal is to create
metrics by which the success of the programs and trainees may be as-
sessed, including the creation of examinations leading to a certiﬁcate of
competence. As mentioned, cancer care in Africa, must compete with a
multitude of other, often more acute, conditions, the IGCS recommends
that these partnerships meet with their respective policy makers, pro-
fessional societies and other stakeholders to plan the roles and career
paths of graduates from these partnership based programs. The Uni-
versity of Michigan, Department of Obstetrics and Gynecology and their
partners in Ghana and Ethiopia have described a robust framework for
partners to work to advance the interests of all parties through and
explicit and open discussion and exploration (Anderson et al., 2014).
The Republic of Rwanda engaged Partners in Health to create a
partnership, or ‘accompaniment’ on a grand scale to combat HIV, TB
and malaria (Binagwaho et al., 2014). As successes were gained and the
‘epidemiologic transition’ from infectious to non-communicable dis-
eases aﬀected Rwanda, the partners expanded their collaboration to
create national cancer hospital in Butaro, Rwanda. Faced with the
challenge of delivering specialty care in a setting with few trained on-
cologists and no established clinical oncology training, the partners
chose to ‘task-shift’: evidence based guidelines were rigorously devel-
oped and followed as medical oﬃcers and nurses made clinical as-
sessments and gave chemotherapy while in close contact with cancer
specialists from the Dana Farber Cancer Center and other collaborating
centers in the U.S. Importantly, medical records were meticulously kept
and outcomes have been measured and published (Tapela et al., 2015).
The American Society of Clinical Oncology (ASCO) supports a
variety of international programs, many of them focused on care de-
livery and capacity building in severely under resourced areas such as
SSA (International Programs-ASCO, n.d.). These programs such as the
IDEA (International Development and Education) awards, support
mentoring and education of oncologists in LMICs by HIC leaders. Other
initiatives support travel-based outreach, such as direct care and
teaching or through lectures. The ASCO also supports academics and
research in LMICS through the journal ‘Global Oncology’, through
mentoring, international fellowship opportunities and through the ‘In-
ternational Innovation Grant’ funding mechanism. Lastly, the ASCO has
partnered with the European Society of Medical Oncology to support
the Global Curriculum in Medical Oncology, providing opportunities to
harmonize and enhance oncology practice globally (Dittrich et al.,
2016).
The AIDS Malignancy Consortium is a clinical trials consortium
sponsored by the U.S. National Cancer Institute's Oﬃce of HIV AIDS
malignancy (https://oham.cancer.gov/oham_research/programs/con-
sortium/). The consortium's International Resource Committee has
been charged to conduct trials in SSA, and has established several new
sites. Through the standards and oversight inherent in this process both
the clinical capacity and the research output of these sites have been
T.C. Randall et al. Gynecologic Oncology Reports 21 (2017) 109–113
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enhanced. Similarly the AIDS Clinical Trials Group sponsors multiple
sites in SSA and has been instrumental in establishing standards of
treatment for HIV associated malignancies (AIDS Clinical Trials Group,
n.d.).
The International Atomic Energy Agency (IAEA) supports capacity
building in radiotherapy through its Human Health Programme (IAEA-
Human Health Programme, n.d.). Particularly through the Program of
Action for Cancer Therapy (PACT) program, the IAEA partners with
low- and middle-income countries to perform assessments of cancer
needs and treatment capacity, often working with countries to draft
national cancer control strategies, and also supports targeted capacity
building projects in both diagnostic and therapeutic radiology.
7. Initiatives From the U.S. National Cancer Institute's Center for
Global Health
The U.S. National Cancer Institute, in response to the growing
challenge of cancer in low- and middle-income countries, established
the Center for Global Health (CGH) in 2011 (Varmus & Trimble, 2011).
The CGH strives to reduce the global burden of cancer through
strengthening global cancer research and resource-appropriate cancer
control strategies, building a cancer research community and through
translating research results into practice (NCI Center for Global Health,
2016). This mission has led to several initiatives that either include or
are speciﬁcally focused on SSA. Through a partnership with the Na-
tional Institute for Biomedical Engineering and Biomedical Imaging and
other U.S. government agencies, the CGH supports the funding for
projects in cancer detection, diagnosis and treatment technologies for
global health (Pearlman et al., 2016a). The P20 Regional Centers for
Research Excellence opportunity seeks to support the development of
cancer research infrastructure and to encourage collaboration among
both HIC and LMIC universities and programs. The CGH and AORTIC
collaborate to support the Beginning Investigator Grant for Catalytic
Research (Big CAT) small grant program, which supports pilot in-
vestigations by new investigators in African Universities partnering
with established investigators from either HICs or LMICs.
The CGH has led two African Cancer Leadership forums, in part-
nership with the International Union for Cancer Control (UICC)
(Pearlman et al., 2016b). In this program leaders from Ministries of
Health and other advocates can make use of technical assistance from
the NCI and UICC and collaborate with peers from other SSA nations to
draft national strategic plans for cancer control. Such plans can lead to
concrete steps and milestones for progress in cancer control.
8. The African Cancer Registry Network
One of the most important steps in cancer control planning is the
development of a population based cancer registry. As discussed, there
are multiple social and environmental factors that may aﬀect the dis-
tribution and burden of cancer locally and nationally. An accurate and
complete registry enables stakeholders to set priorities, rationally make
investments, and monitor outcomes of programs and investments.
Through the African Cancer Registry Network (AFCRN), Parkin and
colleagues provide training, mentorship and logistical support to new
and established registries (Gakunga & PDACRN, 2015). Through this
program 30 population-based registries are now maintained in 22
African countries.
9. AORTIC
The African Organization for Research and Training in Cancer
(AORTIC) is an African based multinational non-governmental organi-
zation dedicated to the control and palliation of cancer throughout
Africa (Morhason-Bello et al., 2013; Adewole et al., 2014). AORTIC has
formalized its cancer-related mission in the Dakar Declaration re-
garding AORTIC's role in cancer advocacy, cancer care, cancer
education, and cancer research. AORTIC fosters research through the
AORTIC Research Committee. This group has fostered research activ-
ities by developing the African Cancer Leaders Institute (ACLI), which is
aimed at identifying and mentoring future cancer leaders in SSA.
AORTIC has also fostered research activities through its co-sponsorship
with the NIH of the BigCAT grant funding program, the Africa Research
Project Map, the Khayelitsha Cervical Cancer Screening Project (KC-
CSP), and many other Africa-centric initiatives. AORTIC holds biennial
research conferences and more frequent targeted regional conferences
and workshops to support the growing community of cancer re-
searchers working in Africa.
10. ASAP
Limited pathology capacity has been identiﬁed as one of the major
barriers to eﬀective cancer research and cancer control in SSA (Adewole
et al., 2014; Adesina et al., 2013). These limitations not only include
pathology needs for clinical (diagnostic) purposes, but also for research,
conﬁrmation of diagnoses that are required to establish valid cancer
incidence and mortality rates, and a host of other cancer-related needs.
To address this limitation, the African Strategies for Advancing Pa-
thology (ASAP) network has created a set of resources, training mod-
ules, data, and protocols to promote improved pathology capacity in
SSA (http://www.pathologyinafrica.org). ASAP has undertaken a sys-
tematic evaluation of pathology and related clinical pathology re-
sources in SSA. These data are freely available to researchers at the
ASAP web site (http://www.pathologyinafrica.org/data), and could be
useful for planning and evaluation purposes by researchers, ministries
of health, and others.
11. Conclusion
A major epidemiologic transformation is taking place in SSA as
more people survive into adulthood and older age, and as more people
move into cities and live more sedentary lives. This, combined with
challenges in infrastructure and human resources, places people at an
increasing risk for cancer. The obstacles faced are signiﬁcant, but a
growing international community is working together to face them. We
exhort those inspired to join the ﬁght against cancer in Africa to join
these existing eﬀorts. This community can ﬁnd inspiration in the
transformational work of the inspired few who battled HIV and other
infectious diseases in similarly daunting circumstances.
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